Trends In Colorectal Cancer Screening – The Impact Of Health Care Reform: An Interview With Brian Jacobson, MD
Medtech Insight recently spoke with Brian Jacobson, MD, associate professor of medicine at Boston University School of Medicine, and the chair of the American Society for Gastrointestinal Endoscopy’s Health and Public Policy Committee, about trends in colorectal cancer screening and the potential impact that health care reform will have on the colonoscopy market.
You may also be interested in...
With the cost of treating colon cancer in the US projected to reach $20 billion annually by 2020, Exact Sciences hopes to improve colorectal cancer screening and survival rates with Cologuard, the first FDA-cleared noninvasive screening test that analyzes both DNA and blood biomarkers in stool.
The market for capsule endoscopy is one of the fastest growing segments in the multibillion-dollar gastrointestinal endoscopy market. The market opportunity is vast and highly underpenetrated, and an increasing number of competitors, new product innovations, and expanding indications for the technology are positioning capsule endoscopy as a market poised for growth – particularly if the technology is proven and FDA cleared for colon cancer indications.